,34 Despite these promising results, the full spectrum of immune responses elicited by cancer vaccines targeting CD4+ helper T cells remains to be extensively explored in the clinic, particularly considering the plasticity of CD4+ T cell subsets. The gene discussed is CD4; the disease is cancer.